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Abstract 
Background: Malondialdehyde-modified low-density lipoprotein (MDA-LDL) is a predictive 
marker of cardiovascular events in patients with stable angina pectoris. However, little is known 
about this marker in patients with acute coronary syndrome (ACS). We investigated the 
prognostic relevance of MDA-LDL to cardiovascular outcomes in patients with ACS.  
Methods: A total of 370 consecutive patients with ACS who underwent primary percutaneous 
coronary intervention (PCI) were enrolled from October 2009 to September 2014 at Mitoyo 
General Hospital. Serum MDA-LDL levels were examined at admission. The patients were 
divided into three groups according to tertile value of serum MDA-LDL levels. The primary 
outcomes were cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, 
revascularization, and heart failure requiring hospital admission.  
Results: MDA-LDL levels in patients with acute myocardial infarction were significantly greater 
than those in patients with unstable angina pectoris (mean ± standard deviation: 133±48 U/L vs 
157±69 U/L, p=0.001). During follow-up (472 [195–920] days), 82 (22%) events occurred. 
Kaplan–Meier analysis showed that patients in the highest MDA-LDL tertile had the worst 
prognosis (log-rank, p<0.001). Cox regression analysis showed that serum MDA-LDL levels 
were an independent predictor of cardiovascular events after PCI in patients with ACS, even after 
adjustment for age, sex, body mass index, conventional cardiovascular risk factors, other lipid 
biomarkers, statin use on admission, cardiac biomarkers, and presence or absence of multivessel 
disease (hazard ratio: 1.80 per 1 standard deviation U/L increase, 95% confidence interval: 
1.07–3.16, p=0.027). Conclusion: Serum MDA-LDL levels on admission are a significant 
prognostic marker in patients with ACS who undergo successful PCI. 
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Introduction  
Accumulating evidence has shown that oxidized low-density lipoprotein (LDL) is a useful 
marker for cardiovascular disease. Oxidized LDL contributes to atherogenesis in a wide range of 
stages, such as impairing vascular endothelial cells, promoting expression of adhesion factors of 
vascular endothelial cells, and facilitating monocyte migration and accumulation of lipids under 
the vascular endothelium through being captured by macrophages [1]. Previous studies have 
shown that oxidized LDL levels are elevated in patients with coronary artery disease [2,3]. 
Oxidized LDL levels are especially increased in acute coronary syndrome (ACS) compared with 
stable angina pectoris [4]. Furthermore, elevated oxidized LDL levels are predictive of future 
cardiovascular events in healthy men and predict an increased risk of future myocardial 
infarction in apparently healthy people [5]. These reports suggest that oxidized LDL is not only a 
promoter of atherogenesis, but is also an important marker for the severity of cardiovascular 
disease and a predictor of future cardiovascular events. 
Malondialdehyde-modified low-density lipoprotein (MDA-LDL) is one of the major products of 
lipid peroxidation and the most common formation of oxidized LDL. Similar to oxidized LDL, 
many reports have shown that MDA-LDL is an important marker for reflecting the severity of 
cardiovascular disease [6]. MDA-LDL is also a predictor of future cardiac events in patients with 
stable angina pectoris who undergo percutaneous coronary intervention (PCI) [7]. Furthermore, 
MDA-LDL levels are a predictive factor for in-stent restenosis in patients with type-2 diabetes 
with old myocardial infarction or stable angina pectoris after PCI [8]. However, little is known 
about the effect of MDA-LDL on the prognosis of patients with ACS. Therefore, this study aimed 
to investigate whether MDA-LDL levels predict cardiovascular events in patients with ACS after 
successful PCI. 
 
Materials and Methods 
This was a retrospective, single-center study that included patients with ACS who underwent 
successful PCI from October 2011 to September 2014 at Mitoyo General Hospital. We defined 
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ACS as patients with acute myocardial infarction or unstable angina pectoris. Acute myocardial 
infarction was defined as type 1 according to the Third Universal Definition of Myocardial 
Infarction [9]. Unstable angina pectoris was defined when patients had unstable symptoms of 
chest pain (at rest/severe and new onset/crescendo pattern), and there was no detectable release of 
enzymes and biomarkers of myocardial necrosis, with or without changes in electrocardiography. 
A successful PCI was defined, according to the definition of angiographic and procedural success 
in the 2011 ACCF/AHA/SCAI PCI guideline [10]. 
The exclusion criteria of this study were as follows: stable angina pectoris; no available data on 
MDA-LDL; previous PCI or coronary artery bypass graft surgery performed within 6 months; 
allergy or contraindication to antiplatelet agents or contrast media; cardiogenic shock or receiving 
cardiopulmonary resuscitation; comorbid conditions associated with a life expectancy of <1 year; 
and inadequate oral medical treatment therapy, including beta-blockers, 
renin–angiotensin–aldosterone system inhibitors, and statins after PCI. 
After screening 773 patients, 403 were excluded. We excluded 345 patients with stable angina 
pectoris, 8 without successful PCI, 8 without available data of MDA-LDL, 6 with a previous 
history of PCI or coronary artery bypass grafting performed within 6 months, 8 with cardiogenic 
shock, and 28 without adequate oral medical treatment therapy after PCI. A total of 370 patients 
with ACS met the criteria and were included in this study (Figure 1).  
We examined the impact of MDA-LDL for prognosis of patients with ACS in main study, with 
comparing among three groups according to tertile value of serum MDA-LDL levels by using 
following way of analysis. Furthermore, as sub-study, we re-examined the impact of MDA-LDL 
for only patients with acute myocardial infarction by comparing two groups according to the 
median value of serum MDA-LDL levels.  
This study was approved by the institutional ethics committee of Mitoyo General Hospital. All 
patients provided written informed consent for enrolment in this study. This study was conducted 
according to the principles expressed in the Declaration of Helsinki. 
All patients underwent PCI by a 6Fr or 7Fr guiding catheter. The patients received dual 
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antiplatelet agents and 7000 IU of unfractionated heparin just before the procedure, and an 
additional bolus of heparin was administrated during PCI to achieve a target activated clotting 
time >250 seconds every 1 hour. Patients received an intracoronary optimal dose of isosorbide 
dinitrate before coronary angiography (CAG), to prevent coronary spasm, as long as there was no 
hemodynamic instability. Balloons and stents were used depending on the operator’s decision. 
The operator also decided the position and length of the angioplasty according to angiographic 
and intravascular ultrasound findings.  
The patients received optimal medical therapy, such as dual antiplatelet agents and statins after 
PCI, based on Japanese and American College of Cardiology/American Heart Association 
guidelines [11,12]. 
Venous blood samples were collected just before PCI. MDA-LDL levels were measured using an 
enzyme-linked immunosorbent assay (Sekisui Medical Co., Tokyo, Japan) on the basis of the 
same principles reported by Kotani et al [13]. For MDA-LDL measurement, inter- and 
intra-coefficient variants were 6.5% and 9.0%, respectively [14]. Other laboratory parameters 
were measured using standard laboratory techniques with an automatic analyzer. 
The primary endpoint of this study was major adverse cardiac and cerebrovascular events 
(MACCE), including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke 
(ischemic or hemorrhagic), ischemia-driven revascularization, and heart failure requiring hospital 
admission. Coronary revascularization was performed only for severe stenosis (≧90%) or if 
significant myocardial ischemia was proven with an objective modality (i.e., myocardial 
scintigraphy or invasive fractional flow reserve) during follow-up time [15]. We did not treat 
scheduled PCI for residual lesion as revascularization event in this study. Follow-up data were 
collected by a blinded assessment team with no information on the background of the patients 
(H.O. and D.Y.). 
Standard statistical methods were used in this study. Background data are expressed as mean ± 
standard deviation for normally distributed continuous variables or median (interquartile range 
for non-normally distributed continuous variables. We used Student's t-test (between two groups) 
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or one-way analysis of variance (among three groups) for comparing normally distributed 
continuous variables, and Bonferroni correction was used for post-hoc testing. For continuous 
variables with a non-normal distribution, Wilcoxon rank sum test (between two groups) or 
Kruskal–Wallis test (among three groups) were used to examine differences in medians. Discrete 
variables are presented as percentages and frequencies; comparisons were based on the 
chi-square test. The Kaplan–Meier method was used to estimate cumulative adverse events and 
significance was evaluated by using the log-rank test. Cox proportional hazard models were used 
to analyze the relationship of serum MDA-LDL levels and event-free survival after adjustment 
for age, sex, body mass index, and the prevalence of coronary risk factors (hypertension, diabetes 
mellitus, dyslipidemia, and smoking), other lipid biomarkers, statin use on admission, and cardiac 
biomarkers, including peak creatine phosphokinase, brain natriuretic peptide, and presence or 
absence of multivessel disease. Logarithmic transformation was also used for non-normally 
distributed continuous variables to transform them to normally distributed continuous variables 
when we put them into Cox proportional hazard models. A receiver operating characteristic curve 
was constructed to demonstrate the discriminatory power of MDA-LDL levels for pre-specified 
cardiovascular outcome. Variables were considered as significant when p<0.05. We performed 
all analyses in this study using JMP version 9.0 (SAS Institute, Tokyo, Japan) or IBM SPSS 
Statistics version 24 (IBM Corp., Armonk, NY, USA). 
 
Results 
In main analysis, patients with ACS (n=370) were divided into tertile groups according to serum 
MDA-LDL levels (U/L), with the lowest tertile at ≤118 (n=124), the middle tertile at 119–160 
(n=123), and the highest tertile at ≥161 (n=123). 
The baseline characteristics of the study population are shown in Table 1. The mean age was 
71±11 years old and 282 (76%) patients were men. Patients in the highest MDA-LDL group were 
younger and the percentage of smokers (former or current) was significantly higher compared 
with those in the other tertile groups. Body mass index was significantly higher in the highest 
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MDA-LDL group compared with the lowest MDA-LDL group. Furthermore, although the 
highest MDA-LDL tertile group had a higher prevalence of dyslipidemia, they received 
significantly less statin therapy on admission compared with the other 2 groups. With regard to 
the lipid profile, levels of triglyceride, total cholesterol, and low-density lipoprotein cholesterol 
(LDL-C), the ratio of LDL-C to high-density lipoprotein cholesterol (HDL-C), and the ratio of 
MDA-LDL to LDL-C (MDA-LDL/LDL-C ratio) were significantly higher in the highest 
MDA-LDL tertile group compared with the other 2 groups. The ratio of acute myocardial 
infarction was highest in the highest MDA-LDL tertile group, but the ratio of unstable angina 
pectoris was highest in the lowest MDA-LDL tertile group. MDA-LDL levels in patients with 
acute myocardial infarction (n=264) were significantly higher than those in patients with unstable 
angina pectoris (n=106) (133±48 U/L vs 157±69 U/L, p=0.001).  
We performed follow-up CAG for 232 (63%) patients, 6-12 months after PCI (Figure 2). Then 
we performed PCI for 31 patients with severe coronary artery stenosis, and 3 patients with 
75-90% coronary artery stenosis showing positive result in myocardial scintigraphy. We did not 
performed PCI for 6 patients with 75-90% stenosis showing negative result in myocardial 
scintigraphy (n=5), or fractional flow reserve (n=1). Most patients (n=192) did not show 
significant stenosis in follow-up CAG. On the other hand, 138 (37%) patients did not receive 
follow-up CAG, and the detailed reasons of those are shown on Online Table 1. There was no 
significant difference among three groups in the ratio of patients without follow-up CAG (Table 
1), and in the ratio of each detailed reasons for not undergoing follow-up CAG (Online Table 1). 
During the follow-up (median [interquartile range]: 472 [195–920] days), 82 (22%) MACCE 
occurred (Table 2). The incidence of MACCE was highest in the tertile group with the highest 
MDA-LDL levels, followed by the middle and the lowest tertile groups (lowest group: 12, middle 
group: 30, highest group: 40, p<0.001). The number of revascularizations for angina pectoris (49 
events) was highest among MACCE events, and the highest MDA-LDL tertile group showed the 
greatest number of events, followed by the middle and the lowest tertile groups (lowest group: 3, 
middle group: 17, highest group: 29, p<0.001). There were no other significant differences in any 
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type of events among the 3 groups.  
Kaplan–Meier curves for each of the 3 groups after PCI showed a poorer event-free survival rate 
in patients with the highest tertile of MDA-LDL levels, followed by the middle and the lowest 
tertile (log-rank, p<0.001, Figure 3A). However, there were no significant differences in other 
lipid biomarkers, such as total cholesterol, LDL-C, HDL-C, and triglyceride levels, among the 
tertile groups (Figure 3B–E). 
Multivariate Cox regression analysis showed that serum MDA-LDL level on admission was an 
independent predictor for MACCE after PCI in patients with ACS (hazard ratio: 1.80 per 1 
standard deviation [37 U/L] increase, 95% confidence interval: 1.07–3.16, p=0.027) after 
adjustment for age, sex, body mass index , conventional cardiovascular risk factors (hypertension, 
diabetes mellitus, dyslipidemia, and history of smoking), other lipid biomarkers, statin use on 
admission, and cardiac biomarkers, including peak creatine phosphokinase, brain natriuretic 
peptide, and presence or absence of multivessel disease (Table 3). 
The specificity and sensitivity of the correlation between MACCE and serum MDA-LDL levels 
were evaluated using receiver operating characteristic analysis to assess their predictive value. 
Receiver operating characteristic analysis showed that the optimal cut-off level of MDA-LDL 
levels was 135 U/L and the area under the curve was 0.66 (95% confidence interval: 0.60–0.73). 
The predictive sensitivity and specificity of MDA-LDL levels were 76% and 56%, respectively.  
Additionally, we showed the characteristics of patients with acute myocardial infarction 
(sub-study) in Table 4. As similar as main study, the higher MDA-LDL group (≤141 U/L) 
(n=130) showed younger age, higher body mass index, higher prevalence of dyslipidemia and 
poorer lipid profiles significantly, comparing to the lower MDA-LDL group (≥142 U/L) (n=134). 
Moreover, the prevalence of multi-vessel disease was higher in the higher MDA-LDL group, 
comparing to the lower MDA-LDL group. 
The comparison of clinical events between these two group during follow-up time (433 
[186–858] days) is shown in Online Table 2. As similar to main study, the incidence of MACCE 
(n=41 [31%]), and especially revascularization (n=28 [21%]) were significantly higher in the 
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higher MDA-LDL group, comparing to those of the lower MDA-LDL group (n=14 [11%]) (n=6 
[5%]) (p<0.001, respectively).   
Kaplan–Meier curves shows a poorer event-free survival rate in patients with the higher 
MDA-LDL group, comparing to the lower MDA-LDL group (Online Figure 1).  
After adjustment for same factors as main study, multivariate Cox regression analysis showed 
that serum MDA-LDL levels on admission was an independent predictor for MACCE after PCI 
even in patients with acute myocardial infarction (hazard ratio: 3.50 per 1 standard deviation [69 
U/L] increase, 95% confidence interval: 1.27–10.5, p=0.016) (Table 5). 
 
Discussion 
The major findings of this study were as follows. (1) MDA-LDL levels in patients with acute 
myocardial infarction were higher than those in patients with unstable angina pectoris. (2) 
Elevation of serum MDA-LDL levels could be an independent predictor for MACCE in patients 
with ACS undergoing successful PCI. (3) The impact of MDA-LDL on prognosis had been also 
demonstrated, even if it is limited to patients with acute myocardial infarction. To the best of our 
knowledge, this is the first study to demonstrate the relation between serum MDA-LDL levels 
and prognosis after successful PCI in patients with ACS.  
Serum MDA-LDL levels are a useful biomarker for reflecting the severity of coronary artery 
disease [2,16] and the presence of vulnerable plaques [17-19]. Our study showed that the acute 
myocardial infarction rate was higher, and the unstable angina pectoris rate was lower in patients 
with elevated MDA-LDL levels. These results support the clinical utility of MDA-LDL as a 
biomarker for reflecting the severity of coronary artery disease. Serum oxidized LDL levels, 
including MDA-LDL, reflect the presence of vulnerable plaques, but this is a systemic, not focal, 
effect. Therefore, elevated MDA-LDL levels might be the result of vulnerable plaques of other 
areas, such as the carotid artery, brain vessels, and arteries of the lower limbs. Additionally, our 
study showed poorer lipid balance and a higher body mass index in the highest MDA-LDL tertile 
group. Recent studies have shown that MDA-LDL levels show positive correlations with LDL-C 
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and triglyceride levels, and a negative correlation with HDL-C levels [20-22]. Furthermore, 
Holvoet et al reported that hyperinsulinemia and impaired glycemic control, reflecting the 
severity of metabolic syndrome, were associated with increased in vivo LDL oxidation [23]. Our 
results are in good agreement with these previous reports.  
The MDA-LDL/LDL-C ratio, which is an indicator of the extent of LDL oxidation, was higher in 
patients with elevated MDA-LDL levels, especially in the highest tertile. Other reports have 
shown that in addition to MDA-LDL levels, the MDA-LDL/LDL-C ratio was higher in patients 
with CAD compared with patients without CAD [20,24]. Our study suggested that in patients 
with ACS, higher MDA-LDL levels also reflected a higher MDA-LDL/LDL-C ratio, which could 
represent a stronger atherogenic state.  
Our study also showed that the onset age of ACS was younger in the highest MDA-LDL group. 
This finding suggests that younger patients with ACS have poor lipid balance and strong 
oxidative stress, and these factors could contribute to their younger onset of ACS. Ogawa et al 
studied patients who underwent CAG, including CAD and normal coronary arteries [22]. These 
authors found that there was a negative correlation between MDA-LDL levels and age, similar to 
our study. However, Toshima et al reported that there was no significant correlation between 
oxidized LDL levels and age in patients with CAD [25]. Additionally, Holvoet et al reported that 
oxidized LDL and MDA-LDL levels were positively correlated with age in patients with ACS, 
stable angina pectoris, and heart transplant, as well as in controls [2]. Further studies are required 
to determine the correlation between MDA-LDL levels and age, especially in patients with ACS.  
Our study showed that in patients with ACS, elevated MDA-LDL levels were able to predict 
future events of MACCE, especially revascularization after PCI. Few other studies have focused 
on the relation between MDA-LDL levels and prognosis of patients with CAD [7-8]. Ito et al 
reported that MDA-LDL levels were significantly associated with future cardiac events after PCI 
with drug-eluting stents in patients with stable angina pectoris under lipid-lowering therapy [7]. 
A recent study that used optical coherence tomography showed that MDA-LDL levels were 
correlated with the presence of thin-cap fibroatheromas in the culprit lesion [18]. Another report 
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on integrated backscatter intravascular ultrasound showed that higher MDA-LDL levels 
suggested the presence of a plaque with greater lipid and lower fibrous content in culprit lesions 
[19]. Moreover, Sahara et al reported that soft plaques, namely lipid-rich plaques, detected on 
intravascular ultrasound were the strongest predictor of in-stent restenosis [26]. This was because 
soft plaques could be compressed more easily by stenting, but also caused proliferation of the 
neointima, and resulted in restenosis. Higher MDA-LDL levels in patients with ACS before PCI 
suggest the presence of soft and vulnerable plaques in the culprit lesion and/or the entire coronary 
artery. This could be a high-risk marker for predicting the future event of in-stent restenosis and 
progression of other lesions, which cause angina pectoris requiring revascularization. However, 
Naruko et al reported that although oxidized LDL levels at discharge were significantly 
correlated with in-stent restenosis at a 6-month follow-up in patients with acute myocardial 
infarction, oxidized LDL levels at admission did not show a significant correlation with future 
cardiac events [27]. Further studies are required to conclude whether MDA-LDL levels at 
admission or discharge are appropriate for predicting future cardiovascular events after PCI in 
patients with ACS. 
There are several limitations to this study. First, this was a single-center, retrospective study and 
the sample size was relatively small. Second, most of the differences among the tertile groups 
occurred in soft endpoints, such as revascularization. In our study, body mass index, the ratio of 
smokers, and the prevalence of dyslipidemia were higher in patients with the highest tertile of 
MDA-LDL compared with other 2 groups. There is the possibility that higher MDA-LDL levels 
reflected accumulation of risk factors and that resulted in a higher prevalence of MACCE, 
including revascularization. However, MDA-LDL levels were a significant independent risk 
factor of MACCE after adjustment for these factors in this study. Finally, our study design 
precluded the investigation of a direct causal relationship. To determine this causal relationship 
between MDA-LDL levels and clinical events more directly, long-term interventional studies 
involving therapeutic agents that reduce MDA-LDL levels are warranted.  
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Conclusion 
In patients with ACS, elevated serum MDA-LDL levels could be an important predictor of future 
cardiac events, especially in patients with ACS requiring revascularization after successful PCI.  
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Figure legends 
 
Figure 1. Flow chart showing selection of patients in main study. 
ACS = acute coronary syndrome; CABG = coronary artery bypass grafting; MDA-LDL = 
malondialdehyde-modified low-density lipoprotein; PCI = percutaneous coronary intervention; 
SAP = stable angina pectoris. 
 
Figure 2. Flow chart of patient follow-up in coronary angiography (main study). 
ACS = acute coronary syndrome; PCI = percutaneous coronary intervention.  
 
Figure 3. Kaplan-Meier analysis of cumulative event-free rates after PCI in patients with ACS, 
according to tertile value of serum MDA-LDL (A), total cholesterol (B), LDL-C (C), HDL-C (D), 
triglyceride (E) levels (main study).   
ACS = acute coronary syndrome; HDL-C = high-density lipoprotein cholesterol; LDL-C = 
low-density lipoprotein cholesterol; MDA-LDL = malondialdehyde-modified low-density 
lipoprotein; PCI = percutaneous coronary intervention. 
 
Online Figure 1. Kaplan-Meier analysis of cumulative event-free rates after PCI in patients with 
AMI, according to median of MDA-LDL (sub-study). 
AMI = acute myocardial infarction; MDA-LDL = malondialdehyde-modified low-density 
lipoprotein; PCI = percutaneous coronary intervention. 
 
